Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Mouse|
|Host / Isotype||Goat / IgG|
|Immunogen||Synthetic peptide sequence (RKLEPPPVKQAEL) corresponding to the C-terminus amino acids of BCAR3|
|Purification||Antigen affinity chromatography|
|Storage buffer||TBS, pH 7.3, with 0.5% BSA|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||0.5-2 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with bovine, canine, human and porcine based on sequence homology.
Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
BCAR3; breast cancer anti-estrogen resistance 3; Breast cancer anti-estrogen resistance protein 3; breast cancer antiestrogen resistance 3; dJ1033H22.2 (breast cancer anti-estrogen resistance 3); KIAA0554; NSP2; OTTHUMP00000011961; p130Cas-binding protein AND-34; SH2D3B
AI131758; AND-34; And34; Bcar3